Risk-Based Surveys go live nationally on September 8, and CMS expects roughly 12% of nursing homes
to earn the lighter-touch treatment and a high-performer icon on Care Compare. Rehinged ran the
eligibility screen across every star-rated facility in the country and found that even the most
generous reading of the criteria clears fewer than one in five. Separately, the first proposed update
to FDA's chronic wound product guidance in twenty years landed this week, with a public meeting
already on the calendar for August 25.
Why it matters for vendors: The risk-based survey split is about to become a
publicly visible, quarterly-refreshed segmentation of the entire SNF market — and it happens to sort
almost perfectly along clinical demand lines. The facilities that stay under full survey are larger,
carry more beds, score higher on wound care and staffing need, and face more penalty exposure. If you
sell clinical or compliance solutions into skilled nursing, the 82.7% of facilities that do not
qualify are not the leftovers. They are the market.
Regulatory
Quality & Ratings
Staffing
Risk-Based Surveys go national September 8 — and the eligibility bar is higher than the headline suggests
What happened
CMS confirmed this week that the Risk-Based Survey process announced on July 16 will take effect
nationwide on September 8, 2026. Facilities that qualify receive an abbreviated
recertification survey and a high-performer icon displayed on Nursing Home Care Compare. Eligibility
is re-checked quarterly and requires a five-star overall rating, a staffing rating of at least three
stars, no citations indicating harm or substandard quality of care in the last survey cycle, accurate
data submission, and no recent change of ownership. CMS projects roughly 12% of nursing homes will
qualify at launch. Operators have broadly welcomed the approach while noting the bar is steep; per
CMS, the most common disqualifier beyond the five-star requirement is a health inspection score above
the state median, followed by a staffing rating below three stars.
Why it matters
This is the first time CMS has published a durable, quarterly-refreshed, consumer-visible split of the
SNF market into high performers and everyone else — and it will be visible to referral sources, health
plans, and families, not just surveyors. For vendors, the practical effect is a free segmentation
layer. Qualifying facilities have less survey pressure and less urgency to buy compliance and quality
tooling; they are relationship and retention accounts. Non-qualifying facilities now have a named,
public, quarterly-scored reason to fix inspection results and staffing ratings before the next
eligibility check. That is a budget trigger with a date attached.
Rehinged analysis of the 14,572 facilities currently carrying a CMS overall star rating shows
3,032 hold five stars overall. Apply the second published screen — a staffing
rating of three stars or better — and the pool falls to 2,526 facilities, or 17.3%.
That is the ceiling. CMS's own 12% projection implies the harm-citation, inspection-score, and data-accuracy
filters strip out roughly 750 more facilities that clear both star tests. Everything else —
12,046 facilities holding 1,333,130 of the country's 1,554,840 certified beds —
stays under the full survey regime.
2,526
clear both star screens (17.3%)
12,046
remain on full survey
85.7%
of certified beds in the full-survey pool
Star-rating screen versus CMS's projected qualifying rate
Clear five-star + three-star staffing
17.3%
CMS projected to qualify
~12%
Facilities remaining under full survey, largest state markets
The geographic spread is where this gets commercially interesting. Texas has 1,165 rated facilities
and just 74 clear both star screens — 6.4%, the worst rate among the large states.
California, with almost exactly the same facility count, clears 250, or 21.7%.
Florida clears 22.9% and Missouri clears 8.7%. A vendor working a national territory is not selling
into one regulatory environment; a Texas rep will find almost every account still fully surveyed,
while a Florida rep will find roughly one in four accounts newly insulated. Crossing the survey split
against demand scores sharpens it further: facilities staying under full survey average
111 beds versus 87 for the exempt group, and score meaningfully higher on wound care
(37.6 versus 31.3), staffing need (27.9 versus 17.8), and penalty risk (36.3 versus 28.3). The
survey-pressured facility and the high-clinical-need facility are, overwhelmingly, the same facility.
Vendors selling survey readiness, infection control, wound care, and workforce solutions should build
their September and October outreach around Texas, Ohio, Illinois, and Missouri, where the
non-qualifying share is highest and the eligibility gap is the conversation opener.
Watch for: September 8 national implementation, then the first quarterly
re-determination that follows. Two things to track: whether the Care Compare icon starts influencing
hospital and health plan referral steerage, and whether operators just short of the bar begin funding
targeted inspection-remediation and staffing-rating projects to qualify on the next cycle. That second
group is the near-term buying population.
Regulatory
Wound & Infection Care
FDA's chronic wound framework gets its first proposed overhaul in twenty years
What happened
The Wound Care Collaborative Community and the journal Wounds published a proposed addendum
to FDA's chronic cutaneous ulcer and burn wound guidance — the framework that has governed wound
product development since the mid-2000s. Lead author Windy Cole of Kent State University framed the
goal plainly: bring the original guidance up to date so effective therapies reach patients sooner and
with stronger evidence behind them. The addendum pushes on three fronts: preclinical standards
including better animal model selection, trial designs incorporating digital wound assessment and
broader biomarker use, and point-of-care biofilm detection for real-world relevance. Separately, FDA
has a patient-focused
drug development meeting on nonhealing chronic wounds scheduled for August 25.
Why it matters
Evidence standards are a competitive moat in wound care, and this proposal would move where the moat
sits. Digital wound assessment and biofilm detection moving from differentiator to expected trial
infrastructure favors manufacturers who have already invested in measurement technology and
disadvantages products whose evidence base rests on older photographic endpoints. For anyone selling
advanced wound care into skilled nursing, the practical near-term consequence is that clinical claims
will get re-litigated on new terms — and facilities with the heaviest wound burden will be the ones
asked to host the trials and pilot the assessment tools.
Rehinged scores wound care demand for every certified SNF in the country on a 0–100 scale; the
national average sits at 36.6. 2,534 facilities score 50 or higher — the top
roughly one-sixth of the market — and together they hold 309,138 certified beds.
These are not average facilities. They average 2.35 stars overall against a national
mean of 3.01, and run larger at 122 beds versus 107 nationally. High wound burden, weak ratings, and
scale travel together.
2,534
facilities scoring 50+ on wound care demand
309,138
beds in the high-wound-demand pool
2.35
average overall star rating
High wound care demand facilities by state
Raw counts favor the big states, but concentration tells a different story. Michigan runs
35.4% of its facilities in the high wound demand tier and Virginia
33.8%, against 27.1% in California and just 10.3% in Texas — a
three-and-a-half-fold spread that has nothing to do with market size. A rep covering Michigan works
a territory where one in three accounts carries heavy wound burden; a Texas rep works one where one
in ten does. Cross this against the survey story above and the two signals converge:
2,358 of the 2,500 rated high-wound-demand facilities — 94.3% — will remain under full
survey after September 8, versus 82.7% of the market overall. The wound care buyer and the
survey-pressured operator are effectively the same account. Wound care manufacturers should
concentrate clinical evidence programs and trial site recruitment in Michigan, Ohio, and Virginia,
where demand density is highest, and lead commercial conversations with survey exposure rather than
product features — that is the pressure the buyer is actually feeling this quarter.
Watch for: FDA's August 25 patient-focused drug development meeting on nonhealing
chronic wounds, and whether the agency signals it will formally take up the addendum. If digital wound
assessment becomes an expected trial component, expect measurement and imaging vendors to move from
the periphery of wound care procurement to the center of it.